Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
A just revealed clinical trial listing shows Ascentage’s BCL-2 inhibitor being compared against an outdated standard of care.
Results with eftilagimod alpha in first-line head and neck cancer threaten to cloud partnering prospects.
Other projects new to the clinic include Haisco’s USP1 inhibitor and and Avistone’s type II c-MET blocker.
The drug adds a new use to its US label, but Takeda’s 2017 Ariad acquisition still looks expensive.
Checkmate-9DW scores a topline win on overall survival, when failure seemed more likely.
AstraZeneca's quiet, cautious work is followed by a $2bn takeover.